OR WAIT 15 SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Available Guidance and Best Practices for Conducting Forced Degradation Studies
Dan W. Reynolds, PhD
Dan W. Reynolds, PhD, is a research investigator II in the chemical development analytical sciences department at GlaxoSmithKline, Five Moor Dr., PO Box 13398, Research Triangle Park, NC 27709.
Karen M. Alsante, PhD
Karen M. Alsante, PhD, is a senior research investigator at Pfizer Global Research and Development (Groton, CT).
Kevin L. Facchine, PhD
Kevin L. Facchine, PhD, is a team manager in the chemical development analytical sciences department at GlaxoSmithKline.
June F. Mullaney, PhD
June F. Mullaney, PhD, is vice-president at the pharmaceutical development technical operations at GlaxoSmithKline, Five Moore Dr., PO Box 13398, Research Triangle Park, NC 27709.
Michael G. Motto, PhD
Michael G. Motto, PhD, is a director in the analytical research and development department at Pfizer Global Research and Development (Groton, CT).
Todd D. Hatajik
Todd D. Hatajik is a scientist at Pfizer Global Research and Development (Groton, CT).
Participants at a Pharmaceutical Research and Manufacturers of America workshop share their views about the acceptable analytical practices of conducting forced degradation studies.